# Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis

> **NCT05648734** · — · COMPLETED · sponsor: **Mansoura University** · enrollment: 200 (actual)

## Conditions studied

- Post-COVID-19 Syndrome
- Lung Fibrosis

## Interventions

- **DRUG:** Corticosteroids alone
- **DRUG:** Corticosteroids + Colchicine
- **DRUG:** Corticosteroids + Pirfenidone
- **DRUG:** Corticosteroids + Colchicine + Pirfenidone for ≥ 14 days

## Key facts

- **NCT ID:** NCT05648734
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-10
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-09-15
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2022-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05648734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05648734, "Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05648734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*